RecruitingPhase 3NCT07499544

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)

Sponsor

Huahui Health

Enrollment

160 participants

Start Date

Apr 22, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Hepatitis D Infection

Summary

This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.

Eligibility

Min Age: 12 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Delayed treatment with libevitug, a drug called Libevitug 10 mg/kg, and others for people with chronic hepatitis d infection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLibevitug 20 mg/kg

Route of administration: intravenous infusion

DRUGLibevitug 10 mg/kg

Route of administration: intravenous infusion

OTHERDelayed treatment with libevitug

Route of administration: intravenous infusion

Locations(7)

Site 201

Garden Grove, California, United States

Site 101

Changchun, Jilin, China

Site 104

Kashgar, Xinjiang Uygur Autonomous Region, China

Site 103

Ürümqi, Xinjiang Uygur Autonomous Region, China

Site 303

Rawalpindi, Punjab Province, Pakistan

Site 301

Karachi, Sindh, Pakistan

Site 302

Karachi, Sindh, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07499544

Related Trials

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT0720090848 locations

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

NCT0729833027 locations

Find HDV and Determine Its Status in Turkey

NCT062485802 locations